The market for Multiple Sclerosis Drugs is expected to reach US$ 27.38 Bn in 2025.
The Multiple Sclerosis Drugs market is expected to see significant CAGR growth over the coming years,at 6.3%.
The report is forecasted from 2017-2025.
The base year of this report is 2016.
Abbvie, Inc., Acorda Therapeutics, Acorda Therapeutics, Inc., Bayer HealthCare, Biogen are some of the major players in the global market.